Richard F Kefford

Richard F Kefford

UNVERIFIED PROFILE

Are you Richard F Kefford?   Register this Author

Register author
Richard F Kefford

Richard F Kefford

Publications by authors named "Richard F Kefford"

Are you Richard F Kefford?   Register this Author

100Publications

12983Reads

49Profile Views

Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.

Pigment Cell Melanoma Res 2019 Sep 13. Epub 2019 Sep 13.

Department of Biomedical Science, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12824DOI Listing
September 2019

Evaluation of commercial kits for purification of circulating free DNA.

Cancer Genet 2018 12 29;228-229:21-27. Epub 2018 Aug 29.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW 2109, Australia; The Poche Centre, Melanoma Institute Australia, NSW 2065, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22107762183025
Publisher Site
http://dx.doi.org/10.1016/j.cancergen.2018.08.005DOI Listing
December 2018

Oncogenic signaling in uveal melanoma.

Pigment Cell Melanoma Res 2018 11 23;31(6):661-672. Epub 2018 May 23.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12708DOI Listing
November 2018

Interferon Signaling Is Frequently Downregulated in Melanoma.

Front Immunol 2018 21;9:1414. Epub 2018 Jun 21.

Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2018.01414DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021492PMC
June 2018

Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma.

Pigment Cell Melanoma Res 2018 05 7;31(3):404-410. Epub 2017 Dec 7.

Melanoma Institute Australia, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12675DOI Listing
May 2018

Liquid biomarkers in melanoma: detection and discovery.

Mol Cancer 2018 01 17;17(1). Epub 2018 Jan 17.

Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-018-0757-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772714PMC
January 2018

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).

J Clin Oncol 2017 Mar 30;35(8):885-892. Epub 2017 Jan 30.

Sanjiv S. Agarwala, Saint Luke's University Hospital, Easton; Uma N. Rao, Ahmad A. Tarhini, Terry L. Evans, and John M. Kirkwood, University of Pittsburgh Medical Center, Pittsburgh, PA; Sandra J. Lee, and Waiki Yip, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA; Gary I. Cohen, Greater Baltimore Medical Center, Baltimore, MD; Douglas S. Reintgen, Lakeland Regional Cancer Center, Lakeland; Vernon K. Sondak, H. Lee Moffitt Cancer Center, Tampa, FL; Joanna M. Brell, MetroHealth Medical Center, Cleveland; William E. Carson, The Ohio State University Comprehensive Cancer Center, Columbus, OH; Mark R. Albertini, University of Wisconsin Hospital, Madison, WI; Michael B. Atkins, Georgetown Medical Center, Washington, DC; Shaker R. Dakhil, Cancer Center of Kansas, Wichita, KS; Robert M. Conry, University of Alabama at Birmingham, Birmingham, AL; Jeffrey A. Sosman, Vanderbilt University, Nashville; Alberto S. Pappo, Saint Jude Children's Research Hospital Oncology, Memphis, TN; Lawrence E. Flaherty, Wayne State University/Karmanos Cancer Institute, Detroit, MI; Michael G. Smylie, Cross Cancer Institute, Edmonton, Canada; and Richard F. Kefford, Sydney West Area Health Service, Westmead, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.2951DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455684PMC
March 2017

Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis.

Pigment Cell Melanoma Res 2017 01;30(1):68-71

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12557DOI Listing
January 2017

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

Br J Cancer 2016 Nov 6;115(11):1280-1284. Epub 2016 Oct 6.

Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione 'G. Pascale', Via Mariano Semmola, 80131 Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2016.321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129828PMC
November 2016

Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.

Melanoma Res 2016 Apr;26(2):202-4

aCrown Princess Mary Cancer Centre bBlood and Marrow Transplant Service, Department of Haematology cDepartment of Clinical Immunology and Allergy, Westmead Hospital dFaculty of Medicine, The University of Sydney eMelanoma Institute Australia fFaculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000232DOI Listing
April 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

The molecular profile of metastatic melanoma in Australia.

Pathology 2016 Feb 18;48(2):188-93. Epub 2016 Jan 18.

Melanoma Institute Australia, Sydney, NSW, Australia; The University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2015.12.008DOI Listing
February 2016

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

Crit Rev Oncol Hematol 2015 Dec 28;96(3):385-98. Epub 2015 Aug 28.

Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; Faculty of Medicine and Health Science, Macquarie University, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2015.08.021DOI Listing
December 2015

Immune checkpoint inhibitors in melanoma.

Melanoma Manag 2015 Aug 10;2(3):267-284. Epub 2015 Aug 10.

Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.15.17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094677PMC
August 2015

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

Clin Cancer Res 2015 Jul 21;21(14):3140-8. Epub 2015 Jan 21.

Melanoma Institute Australia, North Sydney, New South Wales, Australia. Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2023DOI Listing
July 2015

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

Pigment Cell Melanoma Res 2015 May 22;28(3):245-53. Epub 2014 Dec 22.

Melanoma Institute Australia, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12340
Publisher Site
http://dx.doi.org/10.1111/pcmr.12340DOI Listing
May 2015

New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.

J Clin Oncol 2015 Apr 12;33(11):e52-6. Epub 2014 May 12.

Melanoma Institute Australia; The University of Sydney and Westmead Institute for Cancer Research, Sydney, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.5783DOI Listing
April 2015

Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom.

Hered Cancer Clin Pract 2014 20;12(1):20. Epub 2014 Nov 20.

Dermatology Department and Biochemistry and Molecular Genetics Department, Melanoma Unit, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi I Sunyer (IDIBAPS), Barcelona, Spain ; Centro Investigación Biomédica en Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1897-4287-12-20DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361137PMC
March 2015

Targeted BRAF inhibition impacts survival in melanoma patients with high levels of Wnt/β-catenin signaling.

PLoS One 2014 14;9(4):e94748. Epub 2014 Apr 14.

Melanoma Institute of Australia, Sydney, New South Wales, Australia; The University of Sydney, Sydney, New South Wales, Australia; Westmead Institute for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094748PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3986217PMC
January 2015

Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.

Clin Cancer Res 2015 Jan 4;21(1):98-105. Epub 2014 Nov 4.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead, New South Wales, Australia. Australian School of Advanced Medicine, Macquarie University, New South Wales, Australia. Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-0759DOI Listing
January 2015

Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.

J Immunother 2015 Jan;38(1):37-9

*The Crown Princess Mary Cancer Centre ∥Rheumatology Department, Westmead Hospital †Melanoma Institute Australia ‡Sydney Medical School, The University of Sydney §Westmead Institute for Cancer Research, Westmead Millennium Institute, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00002371-201501000-000
Publisher Site
http://dx.doi.org/10.1097/CJI.0000000000000060DOI Listing
January 2015

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.

Nat Commun 2014 Dec 2;5:5694. Epub 2014 Dec 2.

1] Precision Cancer Therapy Laboratory, Australian School of Advanced Medicine, Macquarie University, Sydney, New South Wales 2109, Australia [2] Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms6694DOI Listing
December 2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.

Melanoma Res 2014 Oct;24(5):501-3

Departments of aDermatology bMedical Oncology, Westmead Hospital cSydney Medical School, The University of Sydney dMelanoma Institute Australia, Sydney, New South Wales, Australia eDepartment of Dermatology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000096DOI Listing
October 2014

The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.

Cancer 2014 Oct 1;120(20):3142-53. Epub 2014 Jul 1.

Melanoma Institute Australia, Sydney, New South Wales, Australia; Department of Medical Oncology, Crown Princess Mary Cancer Center, Westmead Hospital, Sydney, New South Wales, Australia; University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28851DOI Listing
October 2014

Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.

Melanoma Res 2014 Oct;24(5):468-74

aWestmead Hospital bWestmead Institute for Cancer Research, Westmead cMelanoma Institute Australia dSydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000110DOI Listing
October 2014

Reply to M. Perier-Muzet et al.

J Clin Oncol 2014 Oct 2;32(28):3203. Epub 2014 Sep 2.

Melanoma Institute Australia; and Sydney Medical School, The University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.56.8477DOI Listing
October 2014

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors.

Mod Pathol 2014 Sep 17;27(9):1193-202. Epub 2014 Jan 17.

1] Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2013.226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107197PMC
September 2014

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

Clin Cancer Res 2014 Sep 23;20(17):4449-58. Epub 2014 Jun 23.

Melanoma Institute Australia and University of Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, and Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-0887DOI Listing
September 2014

Identification of a melanoma susceptibility locus and somatic mutation in TET2.

Carcinogenesis 2014 Sep 30;35(9):2097-101. Epub 2014 Jun 30.

Department of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA, Channing Division of Network Medicine and Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Department of Epidemiology, Fairbanks School of Public Health, Indiana University, Indianapolis, IN 46202, USA, Simon Cancer Center, Indiana University, Indianapolis, IN 46202, USA and Department of Dermatology, School of Medicine, Indiana University, Indianapolis, IN 46202, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgu140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4146422PMC
September 2014

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Mol Oncol 2014 May 15;8(3):544-54. Epub 2014 Jan 15.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528644PMC
May 2014

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

Clin Cancer Res 2014 Apr 24;20(7):1965-77. Epub 2014 Jan 24.

Authors' Affiliations: Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute; Departments of Medical Oncology and Surgical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia; Disciplines of Pathology, Medicine, and Surgery, Sydney Medical School, The University of Sydney, Sydney; Departments of Melanoma and Surgical Oncology and Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3122DOI Listing
April 2014

Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.

Pathology 2014 Apr;46(3):193-8

1The University of Sydney, Sydney 2Melanoma Institute Australia, North Sydney 3Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia 4Canterbury Health Laboratories, Christchurch, New Zealand 5Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst 6Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAT.0000000000000077DOI Listing
April 2014

Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.

J Clin Oncol 2014 Mar 2;32(8):816-23. Epub 2013 Dec 2.

Lisa Zimmer and Dirk Schadendorf, University Hospital, University Duisburg-Essen, Essen, Germany; Lauren E. Haydu, Alexander M. Menzies, Richard A. Scolyer, Richard F. Kefford, John F. Thompson, and Georgina V. Long, Melanoma Institute Australia; Alexander M. Menzies, Richard A. Scolyer, Richard F. Kefford, and Georgina V. Long, Sydney Medical School, The University of Sydney; Richard A. Scolyer and John F. Thompson, Royal Prince Alfred Hospital; Lauren E. Haydu and John F. Thompson, The University of Sydney; John F. Thompson, Mater Hospital, Sydney; Richard F. Kefford and Georgina V. Long, Westmead Institute for Cancer Research, Westmead Hospital, Westmead, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.5572DOI Listing
March 2014

Intrapatient homogeneity of BRAFV600E expression in melanoma.

Am J Surg Pathol 2014 Mar;38(3):377-82

*Melanoma Institute Australia Discipline of †Medicine §Pathology #Surgery, The University of Sydney Departments of **Melanoma and Surgical Oncology ‡Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital ∥Department of Medicine, Westmead Hospital ¶Westmead Institute for Cancer Research, Westmead Hospital ††The Kinghorn Cancer Centre, Garvan Institute of Medical Research ‡‡St Vincent's Clinical School, University of New South Wales, Sydney, Australia.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/ajsp/2014/03000/Intrapatient_Ho
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/PAS.0000000000000136DOI Listing
March 2014

Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib.

Cancer 2014 Feb 5;120(4):530-6. Epub 2013 Nov 5.

Westmead Hospital, Westmead, Australia; Melanoma Institute Australia, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.28445DOI Listing
February 2014

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Cancer Discov 2014 Jan 21;4(1):69-79. Epub 2013 Nov 21.

1The Division of Dermatology, Department of Medicine, 2Division of Surgical Oncology, Department of Surgery, 3Division of Hematology and Oncology, Department of Medicine, 4Jonsson Comprehensive Cancer Center, 5Department of Molecular and Medical Pharmacology, 6David Geffen School of Medicine, University of California, Los Angeles, California; 7Melanoma Institute of Australia, 8Royal Prince Alfred Hospital, 9Westmead Millennium Institute, and 10Westmead Hospital, University of Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893054PMC
January 2014

Paradoxical oncogenesis: are all BRAF inhibitors equal?

Pigment Cell Melanoma Res 2013 Sep 19;26(5):611-5. Epub 2013 Jul 19.

Melanoma Institute Australia, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12132DOI Listing
September 2013

Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma.

J Clin Oncol 2013 Sep 5;31(26):3205-11. Epub 2013 Aug 5.

Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.49.8691
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.49.8691DOI Listing
September 2013

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.

Pigment Cell Melanoma Res 2013 Jul 13;26(4):518-26. Epub 2013 May 13.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12107
Publisher Site
http://dx.doi.org/10.1111/pcmr.12107DOI Listing
July 2013

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.

Mol Cancer Ther 2013 Jul 3;12(7):1332-42. Epub 2013 May 3.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0011DOI Listing
July 2013

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.

J Clin Oncol 2013 Apr 18;31(12):e215-7. Epub 2013 Mar 18.

Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.7028DOI Listing
April 2013

BRAF inhibitor activity in V600R metastatic melanoma.

Eur J Cancer 2013 Mar 10;49(5):1073-9. Epub 2012 Dec 10.

Melanoma Institute Australia and Westmead Hospital, University of Sydney, 40 Rocklands Road, North Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.11.004DOI Listing
March 2013

p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes.

Pigment Cell Melanoma Res 2013 Mar 24;26(2):236-46. Epub 2013 Jan 24.

Westmead Institute for Cancer Research, The University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12062DOI Listing
March 2013

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

Am J Surg Pathol 2013 Jan;37(1):61-5

Melanoma Institute Australia and Westmead Hospital, 40 Rocklands Rd, North Sydney, NSW 2060, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0b013e31826485c0DOI Listing
January 2013

Drug treatment for melanoma: progress, but who pays? Comment.

Med J Aust 2012 Nov;197(9):492

View Article

Download full-text PDF

Source
November 2012

Absence of distinguishing senescence traits in human melanocytic nevi.

J Invest Dermatol 2012 Sep 19;132(9):2226-34. Epub 2012 Apr 19.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2012.126DOI Listing
September 2012

Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma.

Cancer 2012 Sep 26;118(18):4519-29. Epub 2012 Jun 26.

Melanoma Institute Australia, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27693DOI Listing
September 2012

Drug treatment for melanoma: progress, but who pays?

Med J Aust 2012 Aug;197(4):198-9

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5694/mja12.10955DOI Listing
August 2012

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.

J Invest Dermatol 2012 Jul 22;132(7):1850-9. Epub 2012 Mar 22.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute and Melanoma Institute Australia, Westmead Hospital, Westmead, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2012.63DOI Listing
July 2012

Melanoma - a management guide for GPs.

Aust Fam Physician 2012 Jul;41(7):470-3

Surgery (Melanoma and Surgical Oncology), University of Sydney, Melanoma Institute Australia and Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, New South Wales.

View Article

Download full-text PDF

Source
July 2012

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.

Clin Cancer Res 2012 Jun 24;18(12):3242-9. Epub 2012 Apr 24.

Melanoma Institute Australia, Disciplines of Medicine, Surgery, Pathology, and Westmead Institute for Cancer Research, Westmead Millennium Institute, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-12-0052DOI Listing
June 2012

Genome-wide association study identifies three new melanoma susceptibility loci.

Nat Genet 2011 Oct 9;43(11):1108-13. Epub 2011 Oct 9.

Section of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine, Leeds Cancer Research UK Centre, St James’s University Hospital, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.959DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251256PMC
October 2011

Early-life sun exposure and risk of melanoma before age 40 years.

Cancer Causes Control 2011 Jun 7;22(6):885-97. Epub 2011 Apr 7.

Centre for Molecular, Environmental, Genetic and Analytic (MEGA) Epidemiology, Melbourne School of Population Health, University of Melbourne, VIC, Australia.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10552-011-9762-3
Publisher Site
http://dx.doi.org/10.1007/s10552-011-9762-3DOI Listing
June 2011

Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma.

Int J Cancer 2011 May;128(10):2425-35

Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health, University of Melbourne, Melbourne, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.25576DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993823PMC
May 2011

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

J Clin Oncol 2011 Apr 22;29(10):1239-46. Epub 2011 Feb 22.

Melanoma Institute Australia, 40 Rocklands Rd, North Sydney, New South Wales, 2060, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.32.4327DOI Listing
April 2011

Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.

Hum Mutat 2010 Jun;31(6):692-701

Westmead Institute for Cancer Research and Melanoma Institute of Australia, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.21245DOI Listing
June 2010

IGFBP7 is not required for B-RAF-induced melanocyte senescence.

Cell 2010 May;141(4):717-27

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia.

View Article

Download full-text PDF

Source
https://www.systembio.com/downloads/Scurr_2010.pdf
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S009286741000438
Publisher Site
http://dx.doi.org/10.1016/j.cell.2010.04.021DOI Listing
May 2010

A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.

Mol Cancer 2010 Mar 30;9:69. Epub 2010 Mar 30.

Westmead Institute for Cancer research and Melanoma Institute of Australia, University of Sydney at Westmead Hospital, NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-9-69DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856553PMC
March 2010